Date: 2014-04-27
Type of information: Commercialisation agreement
Compound: rasagiline
Company: Teva Pharmaceuticals (Israel) Takeda Pharmaceutical (Japan)
Therapeutic area: Neurodegenerative diseases - CNS diseases
Type agreement: commercialisation
Action mechanism:
- Rasagiline is a monoamine oxidase B (MAO-B) inhibitor which is presumed to act by increasing available synaptic dopamine in the brain which may improve the motor symptoms characteristic of Parkinson’s disease. Teva developed this product and received its first approval in 2005 in Israel and Europe.
Disease: Parkinson's disease
Details:
- • On April. 27, 2014, Teva Pharmaceutical Industries and Takeda Pharmaceutical have signed an agreement allowing Takeda to commercialize Teva’s innovative treatment for Parkinson’s disease, rasagiline (Azilect®) in Japan. Developed by Teva, rasagiline tablets are approved in over 40 countries for the treatment of Parkinson’s disease. Teva received its first approval in 2005 in Israel and Europe, and is currently working towards the acquisition of marketing approval of this product in Japan. Under the terms of the agreement, Takeda will develop rasagiline tablets for the Japanese market and submit a New Drug Application for registration of the product in Japan.
- Teva and Takeda announced an agreement in December 2013, to develop glatiramer acetate for the treatment of multiple sclerosis. Recognizing a high unmet need in the treatment options for Parkinson’s disease in Japan, the two companies have now entered into a further agreement in the CNS category.
Financial terms: The financial details of the agreement are confidential.
Latest news:
Is general: Yes
